Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 3 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 39Neoplasms, Plasma Cell 13Lymphoma 12Neuroblastoma 10Leukemia, Myeloid, Acute 10Lymphoma, Large B-Cell, Diffuse 9Immunoglobulin Light-chain Amyloidosis 8Lymphoma, Non-Hodgkin 6Myelodysplastic Syndromes 5Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, Follicular 5Uveal Melanoma 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Neoplasms 3Melanoma 3Lymphoma, Mantle-Cell 3Leukemia 3Amyloidosis 3Neoplasm Metastasis 2Hodgkin Disease 2Ganglioneuroblastoma 2Venentoclax 1Smoldering Multiple Myeloma 1Sarcoma, Ewing 1Sarcoma 1Retinoblastoma 1Rectal Neoplasms 1Ovarian Neoplasms 1Neuroectodermal Tumors, Primitive, Peripheral 1Neoplasms by Histologic Type 1

Interventions

Lenalidomide 3daratumumab 2Dexamethasone 2dexamethasone acetate 1dexamethasone 21-phosphate 1auricularum 1Watchful Waiting 1Stem Cell Transplantation 1Peripheral Blood Stem Cell Transplantation 1Observation 1Melphalan 1Maintenance 1Calcium Dobesilate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Smoldering Multiple Myeloma × Melphalan × Clear all
NCT00114101 2026-04-29

Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant

National Cancer Institute (NCI)

Phase 3 Active not recruiting
460 enrolled 11 charts
Plasma cell

Smoldering Multiple Myeloma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡